ArticlePostepy dermatologii i alergologii2014
Loss of asthma control after cessation of omalizumab treatment: real life data.
Article in Postepy dermatologii i alergologii, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.British journal of clinical pharmacology · 2018Trial
- Drug survival of omalizumab in atopic asthma: Impact of clinical and genetic variables.Human vaccines & immunotherapeutics · 2025Observational
- Linking IgE and mast cells in pediatric allergic multimorbidity: omalizumab as a therapeutic strategy for asthma and cow's milk allergy.Central-European journal of immunology · 2025Article
- Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma.Frontiers in allergy · 2025Article
- Resveratrol in the treatment of asthma based on an animal model.Postepy dermatologii i alergologii · 2022Review
- Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma.Journal of personalized medicine · 2022Review
- Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.The journal of allergy and clinical immunology. In practice · 2021Article
- Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma.Postepy dermatologii i alergologii · 2019Article
- Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic.Postepy dermatologii i alergologii · 2019Article
- Evaluation of Bayesian classifiers in asthma exacerbation prediction after medication discontinuation.BMC research notes · 2018Article
- Biologic agents for severe asthma patients: clinical perspectives and implications.Internal and emergency medicine · 2018Review
- Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study.Postepy dermatologii i alergologii · 2017Article
- Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential.Therapeutic advances in chronic disease · 2016Review
- Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience.BMC pulmonary medicine · 2016Observational
- Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.BMC pulmonary medicine · 2016Article
- Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia.Postepy dermatologii i alergologii · 2015Article
- Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland.Archives of medical science : AMS · 2015Article
- Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations.Lung India : official organ of Indian Chest Society · 2015Article
- Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report.Postepy dermatologii i alergologii · 2014Article
- Omalizumab in an allergology clinic: real life experience and future developments.Postepy dermatologii i alergologii · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMany clinical and observational studies have demonstrated effectiveness of omalizumab (OMA) in the treatment of severe asthma, but the optimal duration of the therapy remains unknown.
aimThe article presents the authors' clinical experience on OMA cessation in routine practice. MATERIAL AND
methodsDue to new reimbursement criteria, OMA therapy has been interrupted in 11 subjects (6 women/5 men). The mean age of patients was 50.73 ±14.16 years, the mean time of severe asthma duration was 13.54 ±6.05 years. All of them had an excellent/good response to OMA. The duration of OMA therapy was 67.73 ±11.64 months.
resultsNine out of 11 patients had severe asthma exacerbation within the first 5 months after the OMA withdrawal. The mean time to the first severe exacerbation was 7.56 ±2.67 weeks. Between the time of OMA cessation and the time of reassessment, the mean score of Asthma Control Questionnaire increased from 2.58 ±0.71 to 3.63 ±1.26 points and the mean score of Asthma Quality of Life Questionnaire decreased from 4.3 ±1.91 to 3.18 ±1.17 points. The mean oral corticosteroids (OCS) dose increased from 4.61 ±3.0 mg/day to 33.33 ±13.12 mg/day. The number of exacerbations within the last 12 months increased from 1.6 ±0.67 to 5.2 ±1.4, and the number of hospitalizations or emergency room (ER) attendence increased from 0.11 ±0.31 to 1.56 ±1.26.
conclusionsThese data indicate that the withdrawal of OMA therapy after the successful long-term therapy may cause severe asthma exacerbations. Therefore, the decision regarding cessation of OMA treatment should be undertaken individually after careful weighing benefits and risks, especially in patients with a long history of severe asthma, treated with high doses of OCS before OMA introduction, near-fatal asthma events and/or aggravation of asthma during previous episodes of interruptions in OMA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.